Incyte Corp. (INCY)
103.54
+2.90
(+2.88%)
USD |
NASDAQ |
Jun 09, 15:32
Incyte SG&A Expense (Quarterly) : 328.09M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 322.55M |
| BioMarin Pharmaceutical, Inc. | 258.30M |
| Vertex Pharmaceuticals, Inc. | 493.70M |
| Mirum Pharmaceuticals, Inc. | 96.33M |
| Biogen, Inc. | 607.30M |